Business Context and Reporting Period
Company: Eli Lilly & Co.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: September 30, 1998
Reporting Scope: Consolidated results for the three and nine months ended September 30, 1998, compared to the same periods in 1997.
Key Financial Metrics
| Metric (in millions) | 3 Months Ended Sep 30, 1998 | 9 Months Ended Sep 30, 1998 |
|---|---|---|
| Net Sales | $2,573.2 | $7,183.0 |
| Net Income | $518.2 | $1,530.6 |
| Earnings Per Share (Diluted) | $0.46 | $1.36 |
| Operating Cash Flow (9 Months) | $1,574.3 | |
| Total Debt (Short + Long Term) | $2,666.3 | |
| Cash & Cash Equivalents | $1,543.5 | |
| Cost of Sales Margin | 25.9% | 26.4% |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 19% in Q3 and 18% for the nine-month period compared to 1997. Growth was driven by volume increases (17.6% in Q3) and price increases (3.1% in Q3), partially offset by unfavorable exchange rates.
- Profitability: Net income rose 13% in Q3 ($518.2M vs. $456.9M) and turned from a net loss of $842.6M in the prior year's nine-month period to a net income of $1,530.6M. The 1997 loss was heavily impacted by a $2.4 billion asset impairment charge related to PCS Health Systems.
- One-Time Expenses: Q3 1998 included a $127.5 million non-recurring charge for acquired technology related to a collaboration with ICOS Corporation for PDE5 inhibitors.
- Product Performance:
- Prozac: Sales increased 12% in Q3 and 11% for the nine months.
- Zyprexa: Sales increased significantly, up $194 million in Q3 and $548 million for the nine months.
- Anti-infectives: Sales declined 9% in Q3 due to generic competition.
- Debt and Liquidity: Total debt increased by $112 million year-over-year, primarily due to $1.49 billion in stock repurchases during the first nine months of 1998.
Guidance, Outlook, and Risks
- Outlook: Management expects full-year 1998 cost of sales to be below 1997 levels. R&D expenses are expected to increase 23-25% over 1997 levels (excluding ICOS costs). The estimated effective tax rate for the full year was revised to approximately 23%.
- Share Repurchases: The company expects to complete a previously announced $2 billion share repurchase program by the end of 1998.
- Legal Contingencies:
- Prozac Patent Litigation: Four generic manufacturers (Barr, Geneva, Zenith, Teva) have challenged Lilly's patents. Trials are scheduled for January 1999. An unfavorable outcome could materially affect financial position.
- Product Liability: Ongoing lawsuits regarding diethylstilbestrol and Prozac. Accruals of approximately $329 million are recorded, with estimated insurance recoveries of $243 million.
- Antitrust: Settlements reached in federal class actions and many state cases regarding retail pharmacy pricing; some state cases remain pending.
- Year 2000 (Y2K) Readiness: Estimated total program cost is $160-190 million. The company anticipates 95% of critical applications will be ready by January 31, 1999. Failure to remediate could materially disrupt operations.
- Euro Conversion: The company is addressing system and operational impacts of the Euro adoption in 1999, though costs are not expected to be material.
Investor Verification Checklist
- Verify the outcome of the Prozac patent litigation trials scheduled for January 1999 against Barr, Geneva, Zenith, and Teva.
- Monitor the completion status of the $2 billion share repurchase program.
- Track the progress of Year 2000 remediation efforts and associated costs against the $160-190 million estimate.
- Review the impact of generic competition on anti-infective sales (Cefaclor, Vancocin) and Axid sales.
- Confirm the sustainability of the revised 23% effective tax rate for the full year.